← Back to Search

Corticosteroid

Dexamethasone for Sacroiliac Joint Dysfunction

Phase 4
Waitlist Available
Led By Byron Schneider
Research Sponsored by Vanderbilt University Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 months
Awards & highlights

Study Summary

This trial found no difference in efficacy between the two corticosteroids for sacroiliac joint injections.

Eligible Conditions
  • Sacroiliac Joint Dysfunction

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Pain using Numeric Pain Rating Score

Side effects data

From 2013 Phase 4 trial • 122 Patients • NCT01474915
2%
Deep Vein Thrombosis
2%
Cerebrospinal fluid leak
2%
Fever
100%
80%
60%
40%
20%
0%
Study treatment Arm
Ondansetron
Aprepitant

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: DexamethasoneExperimental Treatment1 Intervention
dexamethasone injected into the sacroiliac joint
Group II: TriamcinoloneActive Control1 Intervention
triamcinolone injected into the sacroiliac joint
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Dexamethasone
2007
Completed Phase 4
~2590

Find a Location

Who is running the clinical trial?

Vanderbilt University Medical CenterLead Sponsor
856 Previous Clinical Trials
672,151 Total Patients Enrolled
Byron SchneiderPrincipal InvestigatorAssistant professor
1 Previous Clinical Trials

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What potential hazards are associated with Dexamethasone treatment?

"Owing to its Phase 4 status, the safety of Dexamethasone has been officially sanctioned and is rated a 3 on our team's scale."

Answered by AI

Is it possible to partake in this research?

"To be admitted to this trial, patients must suffer from spondylosis and meet the age requirement of 18 to 99. This medical study is recruiting 102 individuals in total."

Answered by AI

Under what circumstances is Dexamethasone usually prescribed?

"Dexamethasone can be utilised to address synovitis, ophthalmia, sympathetic disturbances and branch retinal vein occlusion."

Answered by AI

Does this research accept volunteers who have reached the age of majority?

"Per the criteria, individuals can enter this trial between 18 and 99 years of age. However, there are 82 studies for younger patients and 538 for those 65 or older."

Answered by AI

What other studies have utilized Dexamethasone to assess its efficacy?

"Presently, Dexamethasone is the subject of 590 clinical trials. Of those ongoing studies, 151 are in Phase 3 development. The majority of these experiments take place in Mishawaka, Indiana; however there exist 18 680 other sites where this medication is being studied."

Answered by AI

What is the current capacity of this medical trial?

"As of right now, this research study is not seeking new enrollees. Initially posted on September 14th 2017 and last updated January 28th 2022, the trial has since ended recruitment. However, there are still 26 studies actively involving participants with spondylosis and 590 with Dexamethasone that may be of interest to you."

Answered by AI

Is there still an opportunity for new participants to join this clinical research?

"Currently, this research initiative is not pursuing new candidates. Initially posted on September 14th 2017 and last updated January 28th 2022, there are no entries for spondylosis that currently need applicants but 590 studies involving Dexamethasone still have open slots."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Particulate Corticosteroid Versus Non-particulate Corticosteroid for Sacroiliac Joint Injection
Byron Schneider 2017. "Particulate Corticosteroid Versus Non-particulate Corticosteroid for Sacroiliac Joint Injection". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03166761.
~5 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top